CytoDyn Picks San Francisco for Next Trial Business Wire
click here to return to Business Wire main menu
DonateNow





CytoDyn Picks San Francisco for Next Trial

Business Wire - November 28, 2005


SANTA FE, N.M. -- CytoDyn, Inc. (OTCBB:CYDY) has tapped Jacob P. Lalezari, MD at Quest Clinical Research in San Francisco, California, as Principal Investigator for the next study of Cytolin(R), a targeted immune therapy for HIV/AIDS, pending FDA approval. Quest Clinical Research has conducted clinical trials for Merck, Bayer, Pfizer, and Roche, among others.

Dr. Lalezari is an Assistant Clinical Professor of Medicine, Department of Medicine, University of California at San Francisco. Previously, he served as Co-Director of the HIV Clinical Research Center at Mt. Zion Medical Center also at the University of California in San Francisco. He is an author of numerous papers on HIV/AIDS, and other infectious diseases, published in the major peer-review journals, such as the New England Journal of Medicine and Annals of Internal Medicine.

"Cytolin(R) is the first immune therapy I've seen that has produced a significant reduction in viral burden in preliminary clinical trials," according to Dr. Lalezari. "Previous attempts to develop an immune therapy for HIV disease have failed in this regard, leaving the treating physician without an immune-based drug for treating HIV/AIDS. I became interested in this project because of its potential for making a new class of drugs available for those living with AIDS," Dr. Lalezari added.

"We are gratified by the interest of a Principal Investigator with the clinical research experience of Dr. Lalezari, and we look forward to working with him," said Allen D. Allen, CEO of CytoDyn.

www.cytodyn.com

MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5027783

CONTACT: CytoDyn, Inc.

Corinne Allen, 505-988-5520

SOURCE: CytoDyn, Inc.
051128
BW051119


Copyright © 2005 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .